Medicare ‘Maximum Fair Price’ And The Importance Of Choosing The Right Therapeutic Alternatives
Biopharma industry raises alarm that Medicare might identify therapeutic comparators for drugs selected for price negotiation based mainly on costs.
You may also be interested in...
Medicare Price Offers, Due Feb. 1, Will Be Informed By Therapeutic Alternatives; That’s A Tall Order
Analysis of therapeutic alternatives to Amgen’s Enbrel highlights the complexities involved in identifying appropriate comparators.
The government’s rush to stand up the negotiation program by the fall likely means an approach to cost effectiveness will be left out of at least the first cycle. But it could be incorporated over time.
The Pink Sheet's updated guide to comment deadlines and decision dates for Medicare's new drug pricing program.